Who are BE-PEP Bedaquiline's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Bedaquiline (B), BPaL, Bedaquiline Oral Tablet.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/be-pep-bedaquiline.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

BE-PEP Bedaquiline — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BE-PEP Bedaquiline (BE-PEP Bedaquiline) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ATP synthase inhibitor. Area: Infectious Disease.

phase 3 ATP synthase inhibitor Mycobacterial ATP synthase Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

BE-PEP Bedaquiline (BE-PEP Bedaquiline) — Institute of Tropical Medicine, Belgium. Bedaquiline inhibits bacterial ATP synthase, disrupting energy production in Mycobacterium tuberculosis.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
BE-PEP Bedaquiline TARGET	BE-PEP Bedaquiline	Institute of Tropical Medicine, Belgium	phase 3	ATP synthase inhibitor	Mycobacterial ATP synthase
Bedaquiline (B)	Bedaquiline (B)	Shenzhen Third People's Hospital	marketed	ATP synthase inhibitor	Mycobacterial ATP synthase
BPaL	BPaL	Otsuka Pharmaceutical Development & Commercialization, Inc.	phase 3	Antituberculous combination therapy	Mycobacterial ATP synthase (bedaquiline), mycobacterial DNA/proteins (pretomanid), bacterial ribosome (linezolid)
Bedaquiline Oral Tablet	Bedaquiline Oral Tablet	Wits Health Consortium (Pty) Ltd	phase 3	ATP synthase inhibitor	Mycobacterial ATP synthase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ATP synthase inhibitor class)

Institute of Tropical Medicine, Belgium · 1 drug in this class
Shenzhen Third People's Hospital · 1 drug in this class
Wits Health Consortium (Pty) Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BE-PEP Bedaquiline — Competitive Intelligence Brief. https://druglandscape.com/ci/be-pep-bedaquiline. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab